E-mail not displaying correctly? View it in your browser.
Our Products
& Services

Click to find
more about our

In this newsletter

New application note:
Accelerating 3D microtissue production

In collaboration with our partner INTEGRA Biosciences, we have just released a new application note illustrating how efficiently 3D microtissues can be produced using InSphero's GravityPLUS plates and INTEGRA's new Viaflo 96 electronic hand-held pipetting system. If you want to speed up your 3D microtissue production, take a look at the document here.

3D cell culture literature picks – Apr 2012
Again, our applications team has reviewed a small selection of current 3D-cell-culture journal papers this month to keep you up-to-date about recent developments in 3D.

Titles of papers reviewed:
Next InSphero customer workshop on June 11 in Zurich
InSphero's next European Customer Workshop will bring together international experts on 3D cell culture:
  • An in-depth introduction to 3D microtissues and applications
  • NEW: For experienced microtissue users - hands-on labs and lectures on advanced topics including histology and 3D biochemical assays (session runs parallel to the introductory 3D cell culture talks).
  • NEW: Presentations from industrial and academic users of 3D microtissues about results and applications.
This full-day event will be held in Zurich, Switzerland on June 11, 2012, starting at 8:30am. Find registration details and preliminary program here.

InSphero workshop in Copenhagen, Denmark, Feb 2012

Meet InSphero at upcoming fairs & events
Meet the InSphero team at upcoming fairs, conferences and workshops to learn how scaffold-free organotypic 3D microtissues, and 3D optimized assays, accelerate the process of drug discovery and development.

To arrange a meeting or a webinar, or register for a workshop please send us an E-mail.

About InSphero

InSphero is a leading supplier of organotypic, biological in-vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, currently counts 6 of the top ten global pharmaceutical and cosmetics companies as customers, and is helping them implement the company’s patent-pending microtissue technology in their development work-flow. InSphero’s 3D microtissues are scaffold free, highly reproducible and delivered in an automation-compatible 96-well format to replace conventional 2D cell assays for better biological relevance and predictivity. The 3D cancer microtissues reflect tumor physiology and are used routinely for screening. For toxicology and metabolics applications, rat and human 3D liver microtissues predict even rare cases of idiosyncratic toxicology and remain viable for more than 5 weeks for chronic studies. InSphero’s off-the-shelf portfolio of assay-ready microtissues is complemented by custom-made 3D microtissues with a development time of 4-6 weeks and production turnaround of less than 10 days.
InSphero is a spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich. The company was recognized for its scientific and commercial achievements with a number of awards, including the VentureKick award, Heuberger Entrepreneurial Award, CTIstartup certification and the SLAS New Product Award (NPA) 2011 Designation. InSphero is also officially certified to the ISO 9001:2008 standard for its Quality Management System.

Our mailing address is:
InSphero Inc.
74 Orion St
Brunswick, ME 04011-5031

Copyright (C) 2012 InSphero Inc. All rights reserved.